Periodic Safety Update Single Assessment Updates
In December 2015, we published a pharmacovigilance article “Periodic Safety Update Single Assessment (PSUSA) – An Overview” which outlined the process the European Medicines Agency(EMA) take to monitor the safety of medicines in Europe. Periodic safety update reports (PSURs) are pharmacovigilance documents submitted by marketing authorisation holders (MAHs) at defined time points during the post-authorization phase of their medicinal products. PSURs provide a comprehensive and critical analysis of the risk-benefit balance of a medicinal product taking into account new or emerging safety information.
The EMA currently maintains a list known as the “EURD list” which governs the active substances/combinations of active substances and EU reference dates for which PSURs are to be submitted. The EURD list also defines the type of submission procedure for a PSUR single assessment (PSUSA). For nationally authorised products (NAPs), the PSUR submission is made to the relevant National Competent Authorities of the registered member states, the lead member state appointed and the EMA. While for centrally authorised products (CAPs), PSURs are submitted to the EMA only via a central PSUR repository.
In order to determine the type of procedure (CAPs, CAP/NAP, NAPs only), submission dates, PSUSA procedure number and requirements for submission of products referred to in articles 10(1), 10a, 14, 16a of Directive 2001/83/EC as amended, please refer to the EURD list.
However, from 13 June 2016 this central PSUR repository will become mandatory for all PSUR submissions for both NAPs and CAPs. From this date onwards, the MAHs will be required to submit PSURs to the EMA via the PSUR Repository only and there will no longer be any requirement to submit PSURs to National Competent Authorities. As always, MAHs are required to submit PSURs once a medicinal product is authorised in the EU, regardless of its marketing status.
A new version of the PSUR Repository which went live in January can be accessed using the eSubmission Gateway/Web Client. Further information can be found here: http://esubmission.ema.europa.eu/psur/psur_repository.html.
It is now mandatory to include an XML delivery file within the PSUR submission package (i.e. in the relevant ZIP file). The delivery files can be created here: https://psur-repo.ema.europa.eu/psur-ui/prepare/submission.html
Please note that the delivery file name cannot be changed and must remain as originally created i.e. delivery.xml. The mandatory use of the PSUR XML delivery file is introduced to harmonise the submission mechanism for all PSURs and it applies to all types of PSUR and PSUR supplementary information submissions.
In conclusion, for medicinal products registered through CAPs, PSUR submissions to the PSUR Repository are already mandatory. From 13 June 2016, this will also apply to NAPs. In the meantime, PSUR submissions for NAPs are made through both the PSUR Repository and relevant National Competent Authorities in which the medicinal product is registered. The PSUR must be submitted as per CTD style electronic formats i.e. eCTD or NeeS and validated using an appropriate validator. PSURs submitted that are not in CTD format or validated cannot be uploaded into the PSUR Repository.
If you have questions about PSUR submissions or need support with your in-licencing requirements, call or email us here at Acorn Regulatory.
We’ll be glad to help!
Further Reading from Acorn Regulatory
Clinical studies are intended to advance animal health care by identifying the most effective therapies and practices for a given condition, or by advancing our basic understanding of the disease. Much like a clinical study in the human population, a veterinary clinical study involves research that gains information from animal patients.
We have been tracking the role of social media in pharmacovigilance in social media since 2015. We first wrote about it here. 5 years on, we are glad to say that the field has moved on substantially in terms of research into the practical applications of social media in Pharmacovigilance. Regulatory guidance for the industry, however, has yet to be updated.
Acorn Regulatory is a leading regulatory, pharmacovigilance and clinical consultancy company headquartered in Ireland. Our Clinical & Medical team works with the largest and the leading companies in life sciences to assist them in bringing their products to market. The team, led by Dr. Danica Cvetkovic, has written extensively on the issue. In the latest e-book from Acorn Regulatory, we look at the best and most popular articles from our Clinical & Medical team.
Writing a risk management plan (RMP) for the first time can be a daunting task. The RMP is a legally binding regulatory document submitted to health authorities and is a mandatory commitment for all Marketing Authorisation Holders in the European Union. The goal of the RMP is to improve the benefit-risk balance of a medicinal product by combining risk assessment and risk minimisation. The RMP is a complex document, but with the revised RMP module (March 2017), comes the revised EU template for RMPs (rev 2 format) and the RMP is now structured in a clear manner with less repetition and with attention to detail.